Arcellx (ACLX) Appoints Michelle Gilson as CFO

Arcellx, Inc. (NASDAQ: ACLX) today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.

"Michelle's vision, leadership, and experience as a research analyst, which included covering companies in the oncology space, will be an invaluable addition to the existing breadth of talent on our management team," said Rami Elghandour, Arcellx's Chairman and Chief Executive Officer. "Michelle brings a depth of knowledge in capital markets and biotechnology and represents the values we look for in our leaders that made her an ideal fit for Arcellx. On behalf of our organization and Board of Directors, we welcome Michelle to our team. I look forward to the impactful role I know she will play as we continue towards our mission of bringing our cell therapy to market to help as many patients as possible."

Most recently, Ms. Gilson served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, covering biotechnology companies. Prior to joining Canaccord, Ms. Gilson held biotechnology equity research roles at Jefferies, LLC; Instinet, LLC (Nomura Securities); Oppenheimer & Co. Inc.; and Goldman Sachs. Ms. Gilson earned her B.S. in Business Administration from the University of Southern California.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024
• T-Mobile (TMUS) and EQT Announce JV to Acquire Lumos